Pallas Capital Advisors LLC Sells 3,755 Shares of Organogenesis $ORGO

Pallas Capital Advisors LLC trimmed its position in shares of Organogenesis (NASDAQ:ORGO) by 16.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,701 shares of the company’s stock after selling 3,755 shares during the period. Pallas Capital Advisors LLC’s holdings in Organogenesis were worth $72,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after purchasing an additional 841,618 shares during the last quarter. Driehaus Capital Management LLC bought a new position in Organogenesis during the 1st quarter valued at about $7,756,000. Invesco Ltd. grew its holdings in Organogenesis by 779.7% during the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after purchasing an additional 947,705 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Organogenesis by 45.3% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company’s stock valued at $2,884,000 after purchasing an additional 208,038 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Organogenesis by 2.9% in the 4th quarter. Northern Trust Corp now owns 616,089 shares of the company’s stock valued at $1,971,000 after buying an additional 17,196 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ORGO has been the subject of several research reports. BTIG Research reissued a “buy” rating on shares of Organogenesis in a research report on Tuesday, July 15th. Cantor Fitzgerald boosted their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Organogenesis Price Performance

Organogenesis stock opened at $4.72 on Tuesday. The firm has a 50-day moving average of $4.74 and a two-hundred day moving average of $4.26. Organogenesis has a 1 year low of $2.61 and a 1 year high of $6.71. The stock has a market cap of $598.78 million, a price-to-earnings ratio of -33.71 and a beta of 1.75.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The business had revenue of $101.01 million during the quarter, compared to analysts’ expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Research analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.